Are Wall Street Analysts Bullish on Charles River Laboratories Stock?

Valued at a market cap of $7.7 billion, Charles River Laboratories International, Inc. (CRL) is a leading global provider of essential drug discovery, early-stage development, and manufacturing support services to the pharmaceutical, biotechnology, government, and academic sectors. The Wilmington, Massachusetts-based company serves as a vital contract research organization (CRO) that accelerates the life sciences pipeline, assisting in the development of a vast majority of the novel drugs approved by the FDA.

This healthcare company has underperformed the broader market over the past 52 weeks. Shares of CRL have gained 18.2% over this time frame, while the broader S&P 500 Index ($SPX) has soared 27.9%. Moreover, on a YTD basis, the stock is down 19.6%, compared to SPX’s 9.2% rise.